[DOWNLOAD] "Administration of a Glycoprotein Iib/Iiia Receptor Blocker with a Thienopyridine Derivative Does Not Increase the Risk of Thrombocytopenia (1)." by The Ohio Journal of Science ~ eBook PDF Kindle ePub Free
eBook details
- Title: Administration of a Glycoprotein Iib/Iiia Receptor Blocker with a Thienopyridine Derivative Does Not Increase the Risk of Thrombocytopenia (1).
- Author : The Ohio Journal of Science
- Release Date : January 01, 2005
- Genre: Education,Books,Professional & Technical,
- Pages : * pages
- Size : 219 KB
Description
ABSTRACT. The combination of aspirin, a thienopyridine derivative, and a glycoprotein IIb/IIIa receptor inhibitor has become standard therapy for patients undergoing percutaneous coronary intervention (PCI). Recent studies have shown an increased incidence of thrombocytopenia in those patients receiving a high loading dose of clopidogrel (thienopyridine) with abciximab (IIb/IIIa receptor inhibitor) prior to coronary intervention. We reviewed the records of 504 patients who underwent PCI at a large tertiary care hospital and noted an incidence of thrombocytopenia of 4.8% comparable to published historical controls who received abciximab without clopidogrel. In patients undergoing PCI, there was no difference in thrombocytopenia or bleeding complications between patients receiving a high or a low dose of a thienopyridine. We conclude that a high loading dose of a thienopyridine derivative prior to PCI may be administered safely and efficaciously in the setting of concomitant administration of abciximab without an undue risk of thrombocytopenia. INTRODUCTION